
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind Corp's ongoing development of its orphan lung pipeline presents significant opportunities for long-term diversification and revenue growth, enhancing its overall financial outlook. The company’s strategic focus on marketing and education aims to improve the uptake of its products, particularly Afrezza and Tyvaso DPI, which are poised to capture market share and drive serviceable revenues across diabetes and pulmonary diseases. Additionally, the potential approval of the Furoscix auto-injector offers a considerable value driver, further solidifying MannKind's position in the biopharmaceutical landscape.
Bears say
MannKind Corp faces significant challenges that contribute to a negative outlook regarding its stock performance. The recent approval of a competitive product by SQ Innovation, combined with potential third-party challenges and vulnerabilities in intellectual property protection, could adversely impact MannKind's market position and sales. Additionally, delays in commercialization resulting from negative trial outcomes or regulatory issues could further limit the company's prospects and revenue potential in an already competitive landscape.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares